METASTATIC MALIGNANT SOLID NEOPLASM
Clinical trials for METASTATIC MALIGNANT SOLID NEOPLASM explained in plain language.
Never miss a new study
Get alerted when new METASTATIC MALIGNANT SOLID NEOPLASM trials appear
Sign up with your email to follow new studies for METASTATIC MALIGNANT SOLID NEOPLASM, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Early trial tests drug combo to halt advanced cancer growth
Disease control OngoingThis early-stage study aims to find the safest and most effective dose of two oral medications, ceritinib and everolimus, when used together. It involves adults with advanced solid tumors or a specific type of lung cancer (ALK-positive non-small cell lung cancer) that has spread …
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 01, 2026 18:11 UTC
-
Targeted drug trial aims to halt growth of advanced tumors with genetic flaw
Disease control OngoingThis study is testing a drug called adavosertib in people with advanced solid tumors that have spread and have a specific genetic change called SETD2-deficiency. The goal is to see if the drug can shrink or stop the growth of these tumors by blocking enzymes the cancer cells need…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
Early trial tests new drug combo for Tough-to-Treat cancers
Disease control OngoingThis early-stage study aims to find the safest and most effective dose of a new drug, M6620, when given with the chemotherapy drug irinotecan. It is for adults with advanced solid tumors, like certain colorectal, pancreatic, or lung cancers, that have spread or cannot be removed …
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New cancer drug cocktail aims to shrink tough tumors
Disease control TerminatedThis early-phase trial is testing the safety and best dose of a new oral drug, ZEN003694, when given with standard immunotherapy drugs (nivolumab with or without ipilimumab) for people with advanced solid tumors that have stopped responding to other treatments. The goal is to see…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Experimental pill aims to starve advanced cancers by cutting off their fuel supply
Disease control OngoingThis trial is testing whether a pill called telaglenastat can slow or stop the growth of advanced solid tumors that have specific genetic mutations. The drug works by blocking a key nutrient (glutamine) that some cancer cells need to grow. The study is for adults with metastatic …
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Scientists test Double-Punch immune therapy for tough cancers
Disease control OngoingThis early-stage study is testing a new combination of two immunotherapy drugs, pembrolizumab and interleukin-12, for people with advanced solid tumors that have spread or cannot be removed by surgery. The main goals are to find the safest dose and understand the side effects. Re…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Personalized immune cells tested to fight five tough cancers
Disease control TerminatedThis early-stage study aimed to test the safety and early effectiveness of a personalized cell therapy called STIL101. The therapy involved growing a patient's own cancer-fighting immune cells (T-cells) from a tumor sample in a lab and then infusing them back. It was designed for…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
New combo attack targets Cancer's genetic weakness
Disease control OngoingThis early-phase trial is testing a combination of two drugs, avelumab and M6620, for people with advanced solid tumors that have spread or cannot be removed by surgery. The treatment is specifically for cancers with flaws in certain genes responsible for fixing DNA damage inside…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
New drug duo tested in Tough-to-Treat cancers
Disease control TerminatedThis early-stage study is testing the safety and best dose of a new two-drug combination (ZEN003694 and binimetinib) for people with advanced solid tumors that have specific genetic changes in the RAS pathway, including triple-negative breast cancer. The trial aims to see if the …
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
New drug duo aims to outsmart tough cancers
Disease control OngoingThis study tested a two-drug combination (veliparib and topotecan) for people with advanced solid tumors or ovarian cancer that has come back after initial treatment. The first phase aimed to find the safest and most effective dose. The second phase focused on seeing if the combi…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
New drug combo tested for Tough-to-Treat advanced cancers
Disease control OngoingThis early-stage study is testing a new combination of two drugs, AZD8186 and docetaxel, for patients with advanced solid tumors that have specific genetic changes (PTEN or PIK3CB mutations). The main goals are to find the safest and most effective dose and to understand the side…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
Scientists test booster shot for Cancer-Killing cells
Disease control OngoingThis early-stage study is testing the safety of adding a drug called atezolizumab after a personalized immune cell therapy for patients with advanced blood or solid tumor cancers. The goal is to see if the drug helps the transferred immune cells survive longer and fight the cance…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
New Two-Pronged attack on advanced cancers shows promise in early trial
Disease control OngoingThis early-stage trial is testing a new combination of three drugs for patients with advanced solid tumors that have spread and have specific genetic changes (PIK3CA or PTEN). The goal is to see if adding a drug called copanlisib to standard immunotherapy drugs (nivolumab and ipi…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
Withdrawn cancer drug trial never started
Disease control TerminatedThis was an early safety study for an experimental cancer drug called CB-5339. It was designed to find the safest dose and check for side effects in adults with advanced solid tumors or lymphomas that had stopped responding to standard treatments. The study was withdrawn by the s…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
Genetic testing guides brain cancer fight
Disease control TerminatedThis study tests whether using genetic testing to match patients with specific drugs can help control cancer that has spread to the brain. It is for adults with solid tumors (like lung or breast cancer) that have spread to the brain and have certain genetic changes. Patients rece…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
Scientists test new drug cocktails for Tough-to-Treat cancers
Disease control OngoingThis early-stage study is testing the safety and best doses of a drug called neratinib when given with one of three other cancer drugs (everolimus, palbociclib, or trametinib). It is for adults with advanced solid tumors that have specific genetic mutations and have stopped respo…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:27 UTC
-
Scientists test new drug duo to fight tough cancers
Disease control OngoingThis early-stage study is testing a new combination of two drugs, sonidegib and pembrolizumab, for people with advanced solid tumors that have spread. The main goals are to find the safest dose of the combination and see if it helps shrink or control the cancer. The study is enro…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 27, 2026 12:41 UTC
-
New combo therapy trial offers hope for HIV patients with advanced cancers
Disease control OngoingThis is a small, early-stage safety study testing a combination of two cancer drugs, nivolumab and cabozantinib, in people living with HIV who have advanced solid tumors. The main goal is to see if the two-drug combination is safe and tolerable for this specific patient group. Re…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New Two-Drug attack on tough, spreading cancers
Disease control OngoingThis early-stage study is testing a new combination of two drugs, DS3201 and ipilimumab, for people with advanced prostate, bladder, or kidney cancer that has spread. The main goals are to find the safest dose and understand the side effects. Researchers hope the drug combo will …
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
Immunotherapy tested as new hope for rare, Tough-to-Treat cancers
Disease control OngoingThis study tested whether the immunotherapy drug pembrolizumab could help control the growth of rare, advanced cancers that have spread or cannot be removed by surgery. It involved 157 patients with specific rare tumor types who had already tried standard treatments. The goal was…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 27, 2026 12:37 UTC
-
Scientists test new Cancer-Fighting duo in early trial
Disease control OngoingThis early-stage study is testing a new combination of two existing cancer drugs, pembrolizumab and ziv-aflibercept, in patients with advanced solid tumors. The main goal is to find the safest and most effective dose of the combination. Researchers will also look for early signs …
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 25, 2026 14:07 UTC
-
New Triple-Threat cancer therapy enters first human safety tests
Disease control OngoingThis early-stage trial is testing the safety and best dose of a three-drug combination (vemurafenib, cetuximab, and irinotecan) for patients with advanced solid tumors that have spread and carry a specific BRAF gene mutation. The goal is to see if combining these drugs—two that b…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 25, 2026 14:07 UTC
-
Scientists test new combo attack on Tough-to-Treat cancers
Disease control TerminatedThis early-stage trial is testing the safety and best dose of a two-drug combination for people with advanced solid tumors that have a specific gene change called HER2. The study combines a targeted chemotherapy drug (trastuzumab deruxtecan) with a pill that blocks cancer growth …
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 24, 2026 12:03 UTC
-
New immune therapy cocktail tested in fight against advanced cancers
Disease control OngoingThis study is testing the safety and effectiveness of avelumab, an immunotherapy drug, when given in combination with other immune-boosting drugs and sometimes radiation. It is for patients with advanced solid tumors that have spread and who have run out of standard treatment opt…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 23, 2026 15:29 UTC
-
New hope for tough cancers: trial tests drug duo to outsmart resistant tumors
Disease control TerminatedThis study is testing whether adding a targeted drug called ipatasertib to a standard chemotherapy (paclitaxel) can help control advanced solid tumors that have specific genetic changes and have stopped responding to similar chemotherapy drugs. It aims to see if this combination …
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC
-
Scientists test Triple-Threat attack on Tough-to-Treat cancers
Disease control OngoingThis study is testing a new three-part treatment for people with advanced cancers that have spread. It combines a new pill (peposertib), an immunotherapy drug (avelumab), and a short, high-dose course of radiation. The goal is to see if this combination can better control cancer …
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC
-
New drug combo aims to fight back against resistant cancers
Disease control OngoingThis study is testing whether combining two drugs, nilotinib and paclitaxel, can help control advanced solid cancers that have continued to grow or spread despite previous treatment with a similar class of drugs called taxanes. It is for adults whose disease is getting worse. The…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
Double attack on tough cancers: early trial tests combo for patients out of options
Disease control OngoingThis early-stage trial is testing a combination of two drugs, niraparib and dostarlimab, for people with advanced breast, ovarian, pancreatic, or related cancers that have a specific genetic change (BRCA mutation) and have stopped responding to standard treatments. The goal is to…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: University of Washington • Aim: Disease control
Last updated Mar 23, 2026 15:16 UTC
-
Scientists test new drug timing to outsmart resistant cancers
Disease control OngoingThis early-phase study is testing a new way of giving two cancer drugs—one after the other instead of together—to see if it is safe and tolerable for people with advanced solid tumors that have stopped responding to standard treatments. The trial aims to find the best dose and se…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 17, 2026 12:55 UTC
-
Early trial aims to tame tough cancers with Two-Pronged attack
Disease control OngoingThis early-stage study is testing a new drug, ALRN-6924, combined with a standard chemotherapy (paclitaxel) for people with advanced solid tumors that have spread or cannot be removed by surgery. The main goals are to find the safest and most effective dose of this combination an…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 13, 2026 15:06 UTC
-
Scientists test new two- and Three-Drug cocktails against tough cancers
Disease control OngoingThis early-phase study is testing the safety and best doses of combining the cancer drug copanlisib with immunotherapy drugs (nivolumab alone or with ipilimumab). It involves 64 adults with advanced solid tumors or lymphoma that have progressed after standard treatments. The goal…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 11, 2026 14:52 UTC
-
Early trial tests cancer drug safety for patients with organ damage
Disease control OngoingThis early safety study aims to find the right dose and understand the side effects of a new drug combination for people with advanced solid tumors who also have liver or kidney problems. It tests adding a pill called veliparib to standard chemotherapy drugs. The main goal is to …
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 10, 2026 12:52 UTC
-
New drug duo targets 'Undruggable' cancer mutations
Disease control OngoingThis study is testing the safety and effectiveness of combining two oral drugs, trametinib and navitoclax, for patients with advanced solid tumors that have spread and have specific KRAS or NRAS genetic mutations. The goal is to find the best dose and see if the combination can s…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 09, 2026 14:25 UTC
-
Scientists test Triple-Threat drug cocktail against advanced cancers
Disease control OngoingThis early-stage trial is testing a combination of three drugs—copanlisib, olaparib, and durvalumab—in patients with advanced solid tumors that have spread or cannot be removed by surgery. The main goal is to find the safest and most effective dose of this combination for people …
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Feb 25, 2026 15:07 UTC
-
Cement shield for Cancer-Weakened spines
Prevention OngoingThis study is testing if a medical cement procedure can prevent painful spinal fractures in cancer patients whose disease has spread to the spine. Patients at high risk for fracture receive either standard targeted radiation or radiation plus the cement procedure. The goal is to …
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Prevention
Last updated Apr 01, 2026 14:43 UTC
-
Cancer's hidden cost: new program aims to ease financial pain for patients
Symptom relief OngoingThis study tests whether a financial counseling program can reduce money problems and stress for people with cancer and their partners. It compares two groups: one gets basic financial education, and the other gets that plus monthly meetings with a financial counselor. The goal i…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: NA • Sponsor: SWOG Cancer Research Network • Aim: Symptom relief
Last updated Apr 01, 2026 18:11 UTC
-
Can a sugar pill you know is fake ease cancer fatigue?
Symptom relief OngoingThis study is testing if an 'open-label' placebo—a sugar pill that patients know contains no medicine—can help reduce severe fatigue in people with advanced cancer. About 100 participants with significant fatigue were randomly assigned to either start taking the placebo pills rig…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE2, PHASE3 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Apr 01, 2026 14:42 UTC
-
New combo therapy aims to fight the exhausting fatigue of advanced cancer
Symptom relief OngoingThis study is testing whether a combination of home-based exercise and a short course of a steroid medication (dexamethasone) can help reduce severe fatigue in people with advanced cancer. The trial involves 99 participants who will be randomly assigned to do exercise with either…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Apr 01, 2026 14:41 UTC
-
New combo therapy aims to fight debilitating cancer fatigue
Symptom relief OngoingThis study is testing whether a drug called anamorelin, combined with a home exercise program and nutritional counseling, can help reduce severe fatigue in people with advanced, incurable solid tumors. Participants take the drug daily for 6 weeks while following the exercise and …
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Apr 01, 2026 14:41 UTC
-
Can early brain care protect quality of life during cancer treatment?
Symptom relief OngoingThis study tests whether early neuropsychological evaluation and support helps patients with brain metastases maintain their quality of life and thinking abilities after radiation therapy. Researchers are comparing two groups: one receiving specialized neuropsychological care alo…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Symptom relief
Last updated Mar 23, 2026 15:18 UTC
-
Phone support study aims to ease burden for cancer patients and families
Symptom relief OngoingThis study is testing two different ways to help cancer clinics provide a phone-based support program called ENABLE to patients with advanced cancer and their caregivers. The program focuses on improving quality of life by helping with stress, symptoms, communication, and plannin…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: NA • Sponsor: University of Rochester NCORP Research Base • Aim: Symptom relief
Last updated Mar 04, 2026 15:29 UTC
-
Major cancer study tracks COVID's impact on treatment and survival
Knowledge-focused OngoingThis study is observing people who have cancer and also get COVID-19. Researchers are collecting blood samples and health information from nearly 1,900 participants over two years. The goal is to understand how having cancer changes the course of COVID-19, and how getting COVID-1…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 31, 2026 12:12 UTC
-
Cancer experts team up to crack genetic code for better treatments
Knowledge-focused OngoingThis study is testing whether having a team of cancer genetics experts review a patient's tumor test results helps doctors choose more effective treatments. It compares the usual approach where doctors review results alone against having a special 'genomic tumor board' provide ex…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: NA • Sponsor: SWOG Cancer Research Network • Aim: Knowledge-focused
Last updated Mar 31, 2026 12:11 UTC
-
Can they hear us? brain wave study seeks answers for families of dying patients
Knowledge-focused TerminatedThis study uses brain wave monitoring to understand if cancer patients who appear completely unresponsive near the end of life can still hear or understand words. Researchers will measure brain activity in response to speech and other stimuli in 30 patients. The goal is to provid…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:33 UTC
-
The hidden burden: how Cancer's weight loss wears down patients and families
Knowledge-focused OngoingThis study aims to understand how often advanced cancer patients experience severe weight loss and loss of appetite, a condition called cachexia. Researchers are also measuring the emotional and psychological stress this causes for both the patients and their primary family careg…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Mar 25, 2026 14:08 UTC
-
Scientists hunt for Cancer's 'Achilles Heel' to target with immune drugs
Knowledge-focused OngoingThis study aims to learn if two specific markers found in tumor tissue can help doctors predict which patients with advanced solid cancers will benefit most from immunotherapy. Sixteen patients with specific genetic mutations in their tumors will receive the immunotherapy drug ni…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Mar 23, 2026 15:19 UTC
-
Scientists probe how new cancer drug battles tumors
Knowledge-focused OngoingThis is an early, small study to understand how the drug DS-8201a works in the body of patients with advanced HER2-positive cancers. Researchers are giving the drug to 62 patients and taking small tumor samples before and after treatment to see how it affects cancer cells and the…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 23, 2026 15:14 UTC
-
Can a simple video unlock better cancer care decisions?
Knowledge-focused OngoingThis study is testing whether a short educational video can help patients with advanced cancer better understand tumor genomic testing. It involves 243 adults with metastatic breast or lung cancer who are already scheduled for this type of testing. Researchers will measure if wat…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: NA • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Mar 10, 2026 12:53 UTC